Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 3, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted

PR NewswireJun 3 16:05 ET

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

PRNewswireMay 23 08:00 ET

Breakeven On The Horizon For Akebia Therapeutics, Inc. (NASDAQ:AKBA)

With the business potentially at an important milestone, we thought we'd take a closer look at Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) future prospects. Akebia Therapeutics, Inc., a biopharmaceutic

Simply Wall StMay 13 06:29 ET

Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Yahoo FinanceMay 11 09:21 ET

Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview

Yahoo FinanceMay 10 15:27 ET

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 10 15:06 ET